{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T03:34:46Z","timestamp":1782963286921,"version":"3.54.5"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T00:00:00Z","timestamp":1735171200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Xuzhou medical key talent project","award":["XWRCHT20220058"],"award-info":[{"award-number":["XWRCHT20220058"]}]},{"name":"Xuzhou Health Commission","award":["2018TD005"],"award-info":[{"award-number":["2018TD005"]}]},{"name":"Xuzhou Science and Technology Council","award":["KC23174"],"award-info":[{"award-number":["KC23174"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Biol Direct"],"DOI":"10.1186\/s13062-024-00580-0","type":"journal-article","created":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T04:17:35Z","timestamp":1735186655000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["PTGES3 proteolysis using the liposomal peptide-PROTAC approach"],"prefix":"10.1186","volume":"19","author":[{"given":"Shiwei","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fukang","family":"Yuan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Dong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaqi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Mao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yangsui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huansong","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,26]]},"reference":[{"key":"580_CR1","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4137\/CMO.S9926","volume":"8","author":"A Flores","year":"2014","unstructured":"Flores A, Marrero JA. Emerging trends in hepatocellular carcinoma: focus on diagnosis and therapeutics. Clin Med Insights Oncol. 2014;8:71\u20136.","journal-title":"Clin Med Insights Oncol"},{"issue":"10360","key":"580_CR2","doi-asserted-by":"publisher","first-page":"1345","DOI":"10.1016\/S0140-6736(22)01200-4","volume":"400","author":"A Vogel","year":"2022","unstructured":"Vogel A, Meyer T, Sapisochin G, Salem R, Saborowski A. Hepatocellular carcinoma. Lancet. 2022;400(10360):1345\u201362.","journal-title":"Lancet"},{"issue":"4","key":"580_CR3","doi-asserted-by":"publisher","first-page":"910","DOI":"10.1007\/s10620-019-05537-2","volume":"64","author":"M Sayiner","year":"2019","unstructured":"Sayiner M, Golabi P, Younossi ZM. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Dig Dis Sci. 2019;64(4):910\u20137.","journal-title":"Dig Dis Sci"},{"key":"580_CR4","doi-asserted-by":"crossref","unstructured":"He PH, Wan HF, Wan J, Jiang HY, Yang Y, Xie KL et al. Systemic therapies in hepatocellular carcinoma: Existing and emerging biomarkers for treatment response. Front Oncol. 2022;12.","DOI":"10.3389\/fonc.2022.1015527"},{"issue":"15","key":"580_CR5","doi-asserted-by":"publisher","first-page":"4115","DOI":"10.3748\/wjg.v20.i15.4115","volume":"20","author":"A Raza","year":"2014","unstructured":"Raza A, Sood GK. Hepatocellular carcinoma review: Current treatment, and evidence-based medicine. World J Gastroenterol. 2014;20(15):4115\u201327.","journal-title":"World J Gastroenterol"},{"issue":"10127","key":"580_CR6","doi-asserted-by":"publisher","first-page":"1301","DOI":"10.1016\/S0140-6736(18)30010-2","volume":"391","author":"A Forner","year":"2018","unstructured":"Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018;391(10127):1301\u201314.","journal-title":"Lancet"},{"key":"580_CR7","doi-asserted-by":"crossref","unstructured":"Beudeker BJB, Boonstra A. Circulating biomarkers for early detection of hepatocellular carcinoma. Therapeutic Adv Gastroenterol. 2020;13.","DOI":"10.1177\/1756284820931734"},{"issue":"1","key":"580_CR8","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13045-020-00885-3","volume":"13","author":"X Li","year":"2020","unstructured":"Li X, Song Y. Proteolysis-targeting chimera (PROTAC) for targeted protein degradation and cancer therapy. J Hematol Oncol. 2020;13(1):50.","journal-title":"J Hematol Oncol"},{"issue":"10","key":"580_CR9","doi-asserted-by":"publisher","first-page":"1482","DOI":"10.1016\/j.chembiol.2022.08.004","volume":"29","author":"LM Simpson","year":"2022","unstructured":"Simpson LM, Glennie L, Brewer A, Zhao JF, Crooks J, Shpiro N, et al. Target protein localization and its impact on PROTAC-mediated degradation. Cell Chem biology. 2022;29(10):1482\u2013e5047.","journal-title":"Cell Chem biology"},{"key":"580_CR10","doi-asserted-by":"crossref","unstructured":"He F, Ru X, Wen T. NRF2, a Transcription Factor for Stress Response and Beyond. Int J Mol Sci. 2020;21(13).","DOI":"10.3390\/ijms21134777"},{"issue":"5","key":"580_CR11","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1016\/j.bbamcr.2018.02.010","volume":"1865","author":"I Bellezza","year":"2018","unstructured":"Bellezza I, Giambanco I, Minelli A, Donato R. Nrf2-Keap1 signaling in oxidative and reductive stress. Biochim et Biophys acta Mol cell Res. 2018;1865(5):721\u201333.","journal-title":"Biochim et Biophys acta Mol cell Res"},{"key":"580_CR12","doi-asserted-by":"publisher","first-page":"102783","DOI":"10.1016\/j.redox.2023.102783","volume":"64","author":"SY Park","year":"2023","unstructured":"Park SY, Gurung R, Hwang JH, Kang JH, Jung HJ, Zeb A, et al. Development of KEAP1-targeting PROTAC and its antioxidant properties: In vitro and in vivo. Redox Biol. 2023;64:102783.","journal-title":"Redox Biol"},{"issue":"7","key":"580_CR13","doi-asserted-by":"publisher","first-page":"1514","DOI":"10.1016\/j.immuni.2024.04.025","volume":"57","author":"J Mannion","year":"2024","unstructured":"Mannion J, Gifford V, Bellenie B, Fernando W, Ramos Garcia L, Wilson R, et al. A RIPK1-specific PROTAC degrader achieves potent antitumor activity by enhancing immunogenic cell death. Immunity. 2024;57(7):1514\u2013e3215.","journal-title":"Immunity"},{"key":"580_CR14","doi-asserted-by":"crossref","unstructured":"Wang L, Xiao Y, Luo Y, Master RP, Mo J, Kim MC et al. PROTAC-mediated NR4A1 degradation as a novel strategy for cancer immunotherapy. J Exp Med. 2024;221(3).","DOI":"10.1084\/jem.20231519"},{"issue":"22","key":"580_CR15","doi-asserted-by":"publisher","first-page":"10141","DOI":"10.7150\/thno.46985","volume":"10","author":"J Jin","year":"2020","unstructured":"Jin J, Wu Y, Chen J, Shen Y, Zhang L, Zhang H, et al. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics. 2020;10(22):10141\u201353.","journal-title":"Theranostics"},{"key":"580_CR16","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/128_2012_356","volume":"328","author":"SE Jackson","year":"2013","unstructured":"Jackson SE. Hsp90: structure and function. Top Curr Chem. 2013;328:155\u2013240.","journal-title":"Top Curr Chem"},{"issue":"42","key":"580_CR17","doi-asserted-by":"publisher","first-page":"16479","DOI":"10.1074\/jbc.RA118.003578","volume":"293","author":"WMJ Obermann","year":"2018","unstructured":"Obermann WMJ. A motif in HSP90 and P23 that links molecular chaperones to efficient estrogen receptor \u03b1 methylation by the lysine methyltransferase SMYD2. J Biol Chem. 2018;293(42):16479\u201387.","journal-title":"J Biol Chem"},{"key":"580_CR18","doi-asserted-by":"crossref","unstructured":"Rehn AB, Buchner J. p23 and Aha1. Sub-cellular biochemistry. 2015;78:113\u2009\u2013\u200931.","DOI":"10.1007\/978-3-319-11731-7_6"},{"key":"580_CR19","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1007\/978-3-031-14740-1_6","volume":"101","author":"MM Biebl","year":"2023","unstructured":"Biebl MM, Buchner J. p23 and Aha1: Distinct Functions Promote Client Maturation. Subcell Biochem. 2023;101:159\u201387.","journal-title":"Subcell Biochem"},{"issue":"42","key":"580_CR20","doi-asserted-by":"publisher","first-page":"32775","DOI":"10.1074\/jbc.M003504200","volume":"275","author":"T Tanioka","year":"2000","unstructured":"Tanioka T, Nakatani Y, Semmyo N, Murakami M, Kudo I. Molecular identification of cytosolic prostaglandin E2 synthase that is functionally coupled with cyclooxygenase-1 in immediate prostaglandin E2 biosynthesis. J Biol Chem. 2000;275(42):32775\u201382.","journal-title":"J Biol Chem"},{"issue":"1","key":"580_CR21","doi-asserted-by":"publisher","first-page":"295","DOI":"10.1016\/j.molonc.2014.08.014","volume":"9","author":"LQ Cano","year":"2015","unstructured":"Cano LQ, Lavery DN, Sin S, Spanjaard E, Brooke GN, Tilman JD, et al. The co-chaperone p23 promotes prostate cancer motility and metastasis. Mol Oncol. 2015;9(1):295\u2013308.","journal-title":"Mol Oncol"},{"issue":"10","key":"580_CR22","first-page":"1694","volume":"26","author":"V Reebye","year":"2012","unstructured":"Reebye V, Querol Cano L, Lavery DN, Brooke GN, Powell SM, Chotai D, et al. Role of the HSP90-associated cochaperone p23 in enhancing activity of the androgen receptor and significance for prostate cancer. Molecular endocrinology (Baltimore. Md). 2012;26(10):1694\u2013706.","journal-title":"Md)"},{"issue":"21","key":"580_CR23","doi-asserted-by":"publisher","first-page":"8446","DOI":"10.1158\/0008-5472.CAN-10-1590","volume":"70","author":"NE Simpson","year":"2010","unstructured":"Simpson NE, Lambert WM, Watkins R, Giashuddin S, Huang SJ, Oxelmark E, et al. High levels of Hsp90 cochaperone p23 promote tumor progression and poor prognosis in breast cancer by increasing lymph node metastases and drug resistance. Cancer Res. 2010;70(21):8446\u201356.","journal-title":"Cancer Res"},{"key":"580_CR24","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1016\/j.jss.2021.08.033","volume":"271","author":"A Adekeye","year":"2022","unstructured":"Adekeye A, Agarwal D, Nayak A, Tchou J. PTGES3 is a Putative Prognostic Marker in Breast Cancer. J Surg Res. 2022;271:154\u201362.","journal-title":"J Surg Res"},{"issue":"1","key":"580_CR25","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s12967-024-04899-0","volume":"22","author":"Q Yin","year":"2024","unstructured":"Yin Q, Ma H, Dong Y, Zhang S, Wang J, Liang J, et al. The integration of multidisciplinary approaches revealed PTGES3 as a novel drug target for breast cancer treatment. J translational Med. 2024;22(1):84.","journal-title":"J translational Med"},{"key":"580_CR26","doi-asserted-by":"crossref","unstructured":"Jiang W, Wei Q, Xie H, Wu D, He H, Lv X. Effect of PTGES3 on the prognosis and immune regulation in lung adenocarcinoma. Anal Cell Pathol (Amst). 2023;2023:4522045.","DOI":"10.1155\/2023\/4522045"},{"key":"580_CR27","doi-asserted-by":"publisher","first-page":"108954","DOI":"10.1016\/j.intimp.2022.108954","volume":"110","author":"P Gao","year":"2022","unstructured":"Gao P, Zou K, Xiao L, Zhou H, Xu X, Zeng Z, et al. High expression of PTGES3 is an independent predictive poor prognostic biomarker and correlates with immune infiltrates in lung adenocarcinoma. Int Immunopharmacol. 2022;110:108954.","journal-title":"Int Immunopharmacol"},{"issue":"10","key":"580_CR28","doi-asserted-by":"publisher","first-page":"113246","DOI":"10.1016\/j.celrep.2023.113246","volume":"42","author":"S Chen","year":"2023","unstructured":"Chen S, Wu Y, Gao Y, Wu C, Wang Y, Hou C, et al. Allosterically inhibited PFKL via prostaglandin E2 withholds glucose metabolism and ovarian cancer invasiveness. Cell Rep. 2023;42(10):113246.","journal-title":"Cell Rep"},{"issue":"W1","key":"580_CR29","doi-asserted-by":"publisher","first-page":"W242","DOI":"10.1093\/nar\/gkab418","volume":"49","author":"C Li","year":"2021","unstructured":"Li C, Tang Z, Zhang W, Ye Z, Liu F. GEPIA2021: integrating multiple deconvolution-based analysis into GEPIA. Nucleic Acids Res. 2021;49(W1):W242\u20136.","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"580_CR30","doi-asserted-by":"publisher","first-page":"2416","DOI":"10.1016\/j.apsb.2021.04.001","volume":"11","author":"Q Zhu","year":"2021","unstructured":"Zhu Q, Chen Z, Paul PK, Lu Y, Wu W, Qi J. Oral delivery of proteins and peptides: Challenges, status quo and future perspectives. Acta Pharm Sinica B. 2021;11(8):2416\u201348.","journal-title":"Acta Pharm Sinica B"},{"key":"580_CR31","doi-asserted-by":"publisher","first-page":"1237964","DOI":"10.3389\/fimmu.2023.1237964","volume":"14","author":"YY Shi","year":"2023","unstructured":"Shi YY, Dong DR, Fan G, Dai MY, Liu M. A cyclic peptide-based PROTAC induces intracellular degradation of palmitoyltransferase and potently decreases PD-L1 expression in human cervical cancer cells. Front Immunol. 2023;14:1237964.","journal-title":"Front Immunol"},{"issue":"2","key":"580_CR32","doi-asserted-by":"publisher","first-page":"208","DOI":"10.2174\/0929867330666230130121822","volume":"31","author":"H Wang","year":"2024","unstructured":"Wang H, Chen M, Zhang X, Xie S, Qin J, Li J. Peptide-based PROTACs: Current Challenges and Future Perspectives. Curr Med Chem. 2024;31(2):208\u201322.","journal-title":"Curr Med Chem"},{"key":"580_CR33","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.pharmthera.2015.07.003","volume":"154","author":"JD Ramsey","year":"2015","unstructured":"Ramsey JD, Flynn NH. Cell-penetrating peptides transport therapeutics into cells. Pharmacol Ther. 2015;154:78\u201386.","journal-title":"Pharmacol Ther"},{"key":"580_CR34","doi-asserted-by":"publisher","first-page":"105231","DOI":"10.1016\/j.phrs.2020.105231","volume":"162","author":"N Vale","year":"2020","unstructured":"Vale N, Duarte D, Silva S, Correia AS, Costa B, Gouveia MJ, et al. Cell-penetrating peptides in oncologic pharmacotherapy: A review. Pharmacol Res. 2020;162:105231.","journal-title":"Pharmacol Res"},{"issue":"12","key":"580_CR35","doi-asserted-by":"publisher","first-page":"2159","DOI":"10.1002\/prot.24403","volume":"81","author":"D Kozakov","year":"2013","unstructured":"Kozakov D, Beglov D, Bohnuud T, Mottarella SE, Xia B, Hall DR, et al. How good is automated protein docking? Proteins. 2013;81(12):2159\u201366.","journal-title":"Proteins"},{"issue":"2","key":"580_CR36","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/nprot.2016.169","volume":"12","author":"D Kozakov","year":"2017","unstructured":"Kozakov D, Hall DR, Xia B, Porter KA, Padhorny D, Yueh C, et al. The ClusPro web server for protein-protein docking. Nat Protoc. 2017;12(2):255\u201378.","journal-title":"Nat Protoc"},{"key":"580_CR37","doi-asserted-by":"publisher","first-page":"1158490","DOI":"10.3389\/fonc.2023.1158490","volume":"13","author":"H Wang","year":"2023","unstructured":"Wang H, Sun P, Yao R, Zhang W, Zhou X, Yao J, et al. Comprehensive pan-cancer analysis of PTGES3 and its prognostic role in hepatocellular carcinoma. Front Oncol. 2023;13:1158490.","journal-title":"Front Oncol"},{"issue":"8","key":"580_CR38","doi-asserted-by":"publisher","first-page":"5512","DOI":"10.1002\/jcp.30276","volume":"236","author":"M Vaghari-Tabari","year":"2021","unstructured":"Vaghari-Tabari M, Ferns GA, Qujeq D, Andevari AN, Sabahi Z, Moein S. Signaling, metabolism, and cancer: An important relationship for therapeutic intervention. J Cell Physiol. 2021;236(8):5512\u201332.","journal-title":"J Cell Physiol"},{"key":"580_CR39","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.ejpb.2015.03.018","volume":"93","author":"E P\u00e9rez-Herrero","year":"2015","unstructured":"P\u00e9rez-Herrero E, Fern\u00e1ndez-Medarde A. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. Eur J Pharm biopharmaceutics: official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 2015;93:52\u201379.","journal-title":"Eur J Pharm biopharmaceutics: official J Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV"},{"issue":"1","key":"580_CR40","doi-asserted-by":"publisher","first-page":"145","DOI":"10.1186\/s12943-020-01258-7","volume":"19","author":"S Zou","year":"2020","unstructured":"Zou S, Tong Q, Liu B, Huang W, Tian Y, Fu X. Targeting STAT3 in Cancer Immunotherapy. Mol Cancer. 2020;19(1):145.","journal-title":"Mol Cancer"},{"key":"580_CR41","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.canlet.2017.03.001","volume":"396","author":"T Andl","year":"2017","unstructured":"Andl T, Zhou L, Yang K, Kadekaro AL, Zhang Y. YAP and WWTR1: New targets for skin cancer treatment. Cancer Lett. 2017;396:30\u201341.","journal-title":"Cancer Lett"},{"key":"580_CR42","doi-asserted-by":"crossref","unstructured":"Cunningham R, Hansen CG. The Hippo pathway in cancer: YAP\/TAZ and TEAD as therapeutic targets in cancer. Clinical science (London, England: 1979). 2022;136(3):197\u2013222.","DOI":"10.1042\/CS20201474"},{"issue":"6","key":"580_CR43","doi-asserted-by":"publisher","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","volume":"79","author":"M Song","year":"2019","unstructured":"Song M, Bode AM, Dong Z, Lee MH. AKT as a Therapeutic Target for Cancer. Cancer Res. 2019;79(6):1019\u201331.","journal-title":"Cancer Res"},{"issue":"1","key":"580_CR44","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13046-022-02483-2","volume":"41","author":"K Wang","year":"2022","unstructured":"Wang K, Dai X, Yu A, Feng C, Liu K, Huang L. Peptide-based PROTAC degrader of FOXM1 suppresses cancer and decreases GLUT1 and PD-L1 expression. J experimental Clin cancer research: CR. 2022;41(1):289.","journal-title":"J experimental Clin cancer research: CR"},{"issue":"9","key":"580_CR45","doi-asserted-by":"publisher","first-page":"3675","DOI":"10.7150\/ijbs.97397","volume":"20","author":"S Liu","year":"2024","unstructured":"Liu S, Lv Q, Mao X, Dong H, Xu W, Du X, et al. O-GlcNAcylated RALY Contributes to Hepatocellular Carcinoma Cells Proliferation by Regulating USP22 mRNA Nuclear Export. Int J Biol Sci. 2024;20(9):3675\u201390.","journal-title":"Int J Biol Sci"},{"issue":"1","key":"580_CR46","doi-asserted-by":"publisher","first-page":"103387","DOI":"10.1016\/j.drudis.2022.103387","volume":"28","author":"AL Saraswat","year":"2023","unstructured":"Saraswat AL, Vartak R, Hegazy R, Patel A, Patel K. Drug delivery challenges and formulation aspects of proteolysis targeting chimera (PROTACs). Drug Discov Today. 2023;28(1):103387.","journal-title":"Drug Discov Today"},{"issue":"10","key":"580_CR47","doi-asserted-by":"publisher","first-page":"1039","DOI":"10.1021\/ar200036k","volume":"44","author":"P Tanner","year":"2011","unstructured":"Tanner P, Baumann P, Enea R, Onaca O, Palivan C, Meier W. Polymeric vesicles: from drug carriers to nanoreactors and artificial organelles. Acc Chem Res. 2011;44(10):1039\u201349.","journal-title":"Acc Chem Res"},{"key":"580_CR48","doi-asserted-by":"publisher","first-page":"120571","DOI":"10.1016\/j.ijpharm.2021.120571","volume":"601","author":"D Guimar\u00e3es","year":"2021","unstructured":"Guimar\u00e3es D, Cavaco-Paulo A, Nogueira E. Design of liposomes as drug delivery system for therapeutic applications. Int J Pharm. 2021;601:120571.","journal-title":"Int J Pharm"},{"issue":"40","key":"580_CR49","doi-asserted-by":"publisher","first-page":"21860","DOI":"10.1021\/jacs.3c05948","volume":"145","author":"C Song","year":"2023","unstructured":"Song C, Jiao Z, Hou Z, Wang R, Lian C, Xing Y, et al. Selective Protein of Interest Degradation through the Split-and-Mix Liposome Proteolysis Targeting Chimera Approach. J Am Chem Soc. 2023;145(40):21860\u201370.","journal-title":"J Am Chem Soc"},{"issue":"Pt A","key":"580_CR50","doi-asserted-by":"publisher","first-page":"896","DOI":"10.1016\/j.jcis.2024.08.185","volume":"678","author":"W Zhang","year":"2025","unstructured":"Zhang W, Jin Y, Wang J, Gu M, Wang Y, Zhang X, et al. Co-delivery of PROTAC and siRNA via novel liposomes for the treatment of malignant tumors. J Colloid Interface Sci. 2025;678(Pt A):896\u2013907.","journal-title":"J Colloid Interface Sci"},{"key":"580_CR51","doi-asserted-by":"crossref","unstructured":"Wang X, Zhao Y, Li X, Zhang Q, He J, Liu Y et al. Liposomal STAT3-Degrading PROTAC Prodrugs Promote Anti-Hepatocellular Carcinoma Immunity via Chemically Reprogramming Cancer Stem Cells. Nano Lett. 2024 Apr 10.","DOI":"10.1021\/acs.nanolett.4c00201"},{"issue":"18","key":"580_CR52","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.2217\/nnm-2020-0156","volume":"15","author":"A Saraswat","year":"2020","unstructured":"Saraswat A, Patki M, Fu Y, Barot S, Dukhande VV, Patel K. Nanoformulation of PROteolysis TArgeting Chimera targeting \u2018undruggable\u2019 c-Myc for the treatment of pancreatic cancer. Nanomed (London England). 2020;15(18):1761\u201377.","journal-title":"Nanomed (London England)"},{"issue":"1","key":"580_CR53","doi-asserted-by":"publisher","first-page":"e08702","DOI":"10.1016\/j.heliyon.2021.e08702","volume":"8","author":"A Saraswat","year":"2022","unstructured":"Saraswat A, Vemana HP, Dukhande VV, Patel K. Galactose-decorated liver tumor-specific nanoliposomes incorporating selective BRD4-targeted PROTAC for hepatocellular carcinoma therapy. Heliyon. 2022;8(1):e08702.","journal-title":"Heliyon"},{"key":"580_CR54","doi-asserted-by":"publisher","first-page":"115754","DOI":"10.1016\/j.biopha.2023.115754","volume":"168","author":"A Saraswat","year":"2023","unstructured":"Saraswat A, Vartak R, Hegazy R, Fu Y, Rao TJR, Billack B, et al. Oral lipid nanocomplex of BRD4 PROteolysis TArgeting Chimera and vemurafenib for drug-resistant malignant melanoma. Biomed Pharmacother. 2023;168:115754.","journal-title":"Biomed Pharmacother"},{"issue":"3","key":"580_CR55","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.omtn.2024.102292","volume":"35","author":"A Saraswat","year":"2024","unstructured":"Saraswat A, Vemana HP, Dukhande V, Patel K. Novel gene therapy for drug-resistant melanoma: Synergistic combination of PTEN plasmid and BRD4 PROTAC-loaded lipid nanocarriers. Mol therapy Nucleic acids. 2024;35(3):102292.","journal-title":"Mol therapy Nucleic acids"},{"key":"580_CR56","doi-asserted-by":"crossref","unstructured":"Patel A, Saraswat A, Patel H, Chen ZS, Patel K. Palmitoyl Carnitine-Anchored Nanoliposomes for Neovasculature-Specific Delivery of Gemcitabine Elaidate to Treat Pancreatic Cancer. Cancers (Basel). 2022;15(1).","DOI":"10.3390\/cancers15010182"}],"container-title":["Biology Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-024-00580-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13062-024-00580-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13062-024-00580-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,26]],"date-time":"2024-12-26T06:06:17Z","timestamp":1735193177000},"score":1,"resource":{"primary":{"URL":"https:\/\/biologydirect.biomedcentral.com\/articles\/10.1186\/s13062-024-00580-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,26]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["580"],"URL":"https:\/\/doi.org\/10.1186\/s13062-024-00580-0","relation":{},"ISSN":["1745-6150"],"issn-type":[{"value":"1745-6150","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,26]]},"assertion":[{"value":"7 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"We followed the ethical guidelines of Animal Care & Welfare Committee at Southeast University for all animal experiments (approval numbers 20240301009).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"144"}}